Claus Torp Jensen Has Been Appointed First Chief Digital Officer and Head of Technology for Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology. His recruitment follows an expansive national search to identify a leader...
14-Oct-2019 10:00 AM EDT Add to Favorites
New Study Examines Wilms’ Tumor Relapse and May Give Clues to about Which Other Childhood Cancers Could Relapse
Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help...
8-Aug-2019 9:05 AM EDT Add to Favorites
Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report
Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago,...
30-Jul-2019 10:05 AM EDT Add to Favorites
Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis
Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to...
18-Jul-2019 11:05 AM EDT Add to Favorites
Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).
21-Jun-2019 3:00 PM EDT Add to Favorites
Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted Therapeutic
LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase...
1-Apr-2019 4:05 PM EDT Add to Favorites
During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness.
29-Jan-2019 12:05 PM EST Add to Favorites
Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower...
3-Dec-2018 10:05 AM EST Add to Favorites
see all news
2-Dec-2014 12:35 PM EST
9-Dec-2013 9:05 AM EST
3-Dec-2013 3:15 PM EST
20-Sep-2013 2:00 PM EDT
12-Mar-2013 6:00 PM EDT
28-Sep-2012 12:40 PM EDTsee all experts